Search
43 studies match these filters. Showing 1–25 of 43 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT07685808 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed i… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 22 sites in total | Recruiting | Phase 2 | 360target | 22 / 1 | 2026 | Nov 18, 2026 | |
| NCT07784725 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 220 sites in total | Recruiting | Phase 3 | 2,500target | 220 / 16 | 2026 | Oct 30, 2026 | |
| NCT07784270 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 230 sites in total | Recruiting | Phase 3 | 1,500target | 230 / 16 | 2026 | Oct 28, 2026 | |
| NCT07667803 | A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exerci… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 325 sites in total | Recruiting | Phase 3 | 4,500target | 325 / 19 | 2026 | Oct 13, 2026 | |
| NCT07684235 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839). ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 92 sites in total | Recruiting | Phase 3 | 3,200target | 92 / 5 | 2026 | Oct 5, 2026 | |
| NCT07684144 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 45 sites in total | Recruiting | Phase 3 | 950target | 45 / 5 | 2026 | Oct 5, 2026 | |
| NCT07817251 | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months. ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 40 sites in total | Recruiting | Phase 3 | 210target | 40 / 1 | 2026 | Sep 30, 2026 | |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eith… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 303 sites in total | Recruiting | Phase 3 | 2,500target | 303 / 19 | 2026 | Sep 30, 2026 | |
| NCT07619131 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment… ✓ Contact✗ Claimed Nearest site: Derby, Kansas, United States — 54 km away · 152 sites in total | Recruiting | Phase 3 | 600target | 152 / 11 | 2026 | Sep 10, 2026 | |
| NCT07662044 | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucos… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 149 sites in total | Recruiting | Phase 3 | 800target | 149 / 13 | 2026 | Aug 31, 2026 | |
| NCT07654374 | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 74 sites in total · contact listed | Recruiting | Phase 3 | 1,100target | 74 / 1 | 2026 | Oct 20, 2026 | |
| NCT07606066 | A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions. ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 76 sites in total | Recruiting | 2,150target | 76 / 7 | 2026 | Aug 25, 2026 | ||
| NCT07282743 | Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, on… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 21 sites in total | Recruiting | Phase 2 | 285target | 21 / 2 | 2026 | Mar 18, 2026 | |
| NCT07546929 | HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cel… ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 25 sites in total · contact listed | Recruiting | Phase 2 | 300target | 25 / 1 | 2023 | Apr 23, 2026 | |
| NCT07296484 | Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 61 sites in total · contact listed | Recruiting | Phase 2 | 1,500target | 61 / 1 | 2025 | Oct 6, 2026 | |
| NCT07654361 | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calor… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 71 sites in total · contact listed | Recruiting | Phase 3 | 3,600target | 71 / 1 | 2026 | Aug 10, 2026 | |
| NCT07662213 | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 210 sites in total | Recruiting | Phase 3 | 1,200target | 210 / 15 | 2026 | Oct 22, 2026 | |
| NCT07353931 | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last abo… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 147 sites in total · contact listed | Recruiting | Phase 3 | 900target | 147 / 13 | 2026 | Nov 4, 2026 | |
| NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical fun… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 40 sites in total | Recruiting | Phase 3 | 656target | 40 / 2 | 2026 | Nov 5, 2026 | |
| NCT06190717 | Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 23 sites in total · contact listed | Recruiting | Not applicable | 304target | 23 / 1 | 2024 | Oct 28, 2026 | |
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 76 sites in total | Recruiting | Phase 3 | 1,100target | 76 / 1 | 2024 | Oct 15, 2026 | |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasi… ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 563 sites in total · contact listed | Recruiting | Phase 3 | 4,500target | 563 / 34 | 2025 | Oct 8, 2026 | |
| NCT06527222 | A Study of Ranolazine in ALS The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 6 sites in total · contact listed | Recruiting | Phase 2 | 72target | 6 / 1 | 2025 | Nov 18, 2026 | |
| NCT07570316 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody l… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 35 sites in total · contact listed | Recruiting | Phase 3 | 230target | 35 / 3 | 2026 | Nov 3, 2026 | |
| NCT07567001 | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 838 sites in total | Recruiting | Phase 3 | 5,610target | 838 / 27 | 2026 | Aug 18, 2026 |